Angiotensin II not only is a vasoconstrictor, but it also affects cell growth and apoptosis,
inflammation, fibrosis, and coagulation. Blockade of the renin-angiotensin system, either …

The evidence examining the effect of angiotensin‐converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARB s) on mortality in high‐risk patients is conflicting. To …

Objective ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely
prescribed in patients with high cardiovascular (CV) risk. However, whether both classes …

Background: Patients with ischemic heart disease and preserved ventricular function
experience considerable morbidity and mortality despite standard medical therapy. Purpose …

OBJECTIVE: To determine, through a review of the medical literature, whether there is
adequate evidence to support the use of angiotensin receptor blockers (ARBs) in place of …

Conclusions ACEIs have demonstrated clinical benefits when used in a wide range of
cardiovascular disorders. ACEI use reduces mortality after an MI and in heart failure, and are …

The blood-pressure-lowering efficacy of both angiotensin-converting enzyme inhibitors
(ACE-I) and angiotensin II receptor blockers (ARBs) has been clearly demonstrated in recent …

Angiotensin receptor blockers (ARBs), through their physiological blockade of the renin-
angiotensin system, reduce morbidity and mortality associated with hypertension, heart …

Objective: To examine clinical and economic outcomes associated with angiotensin II
receptor blockers (ARB). Methods: Retrospective claims data were analyzed for …

Objective: Although both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II
receptor blockers (ARBs) are well established for the reduction of cardiovascular morbidity …